Global Pharmacogenomics Market, by Technology (Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, and Others), By Application (Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Psychiatry, Pain Management, and Others), and By End User (Hospitals & Clinics, Research Institutions and Academic Institutes and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2034

Pharmacogenomics Market accounted for US$ 20.4 billion in 2024 and is estimated to be US$ 58.3 billion by 2034 and is anticipated to register a CAGR of 12.2%.

The customization of medical treatment to the specific characteristics of each patient refers to pharmacogenomics or personalised medicine. In fact, this concept entails the ability to divide humans into sub-populations that are disproportionately susceptible to a disease or receptive to a therapy. The focus of personalised medicine is on the transition in medicine from reaction to prevention. Individual responses to the medicine differ depending on genetic make-up. The majority of reactions are positive and demonstrate improvement, while only a few people experience adverse effects. To address these differences, researchers must investigate how genes influence drug processing. The study of inherited changes in human genes in response to various medications is known as pharmacogenomics. It employs pharmacology and genomics principles to create effective and safe pharmaceuticals that are tailored to a person's genetic composition. Polymerase chain reaction (PCR), microarray, deoxyribonucleic acid (DNA) sequencing, mass spectrometry, and electrophoresis are some of the technologies used. The genetic testing used in pharmacogenomics are used to determine illness susceptibility and the efficacy of newly discovered medications. Cardiovascular, Alzheimer's, cancer, human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), and asthma are among the disorders for which pharmacogenomics is commonly employed.

Surge in the adoption of pharmacogenomics procedures by healthcare professionals boost the market growth

The global pharmacogenomics market is expected to grow due to an increase in the elderly population, a surge in the adoption of pharmacogenomics procedures by healthcare professionals, growing patient awareness of personalised therapy, and an increase in the prevalence of chronic diseases such as cancer, tuberculosis, HIV, and others. Furthermore, technological improvements connected with molecular diagnostics procedures for a better understanding of the genetic structure of particular patients are likely to drive pharmacogenomics market growth throughout the forecast period. However, factors such as a scarcity of skilled and highly trained healthcare professionals to perform pharmacogenomics diagnostics tests, the high cost of tests, and a lack of funding for research and development of various pharmacogenomics pathways are expected to limit the global pharmacogenomics market's growth.

The Pharmacogenomics Market is segmented based on technology, application, end-user and region.

On the basis of Technology, the Global Pharmacogenomics Market is segmented into Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, and Others. Based on Application, the target market is segmented into Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Psychiatry, Pain Management, and Others. Based on End-User, the target market is segmented into Hospitals & Clinics, Research Institutions and Academic Institutes and Others.

Regional Insights:                                                       

On region the Global Pharmacogenomics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Due to the high per capita healthcare expenditure, high patient awareness levels, and the high prevalence of target diseases, North America is likely to dominate the entire market over the projection period. According to the American Cancer Society, approximately 1.8 million new instances of cancer will be identified in 2020, with 606,520 people dying as a result. Furthermore, the market's expansion is being aided by an increased inclination for tailored treatment, as well as a high adoption rate.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Global Pharmacogenomics Market report based on Technology, Application, End-User and region.

Global Pharmacogenomics Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The prominent players operating in the Global Pharmacogenomics Market include Abbott Laboratories, Dynamic DNA Laboratories, Empire Genomics, LLC, F. Hoffmann-La Roche Ltd., Illumina, Inc., OneOme LLC, Myriad Genetics Inc., OPKO Health, Inc. (GeneDx), and Thermo Fisher Scientific, Inc. The other players included in the value chain analysis (but not included in the report) are Assurex Health Inc., Teva Pharmaceutical Industries Ltd., and Bayer AG.

• Abbott Laboratories
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Dynamic DNA Laboratories
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Empire Genomics, LLC
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Illumina, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• OneOme LLC
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Myriad Genetics Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Thermo Fisher Scientific, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies